Advances in the Management of Acute Venous Thromboembolism and New Therapeutic Agents

Hannah Stevens; James McFadyen; Noel Chan

doi:10.1055/s-0041-1723953

Advances in the Management of Acute Venous Thromboembolism and New Therapeutic Agents

Semin Respir Crit Care Med. 2021 Apr;42(2):218-232. doi: 10.1055/s-0041-1723953. Epub 2021 Feb 18.

Authors

Hannah Stevens^{1

2

3}, James McFadyen^{1

2

3}, Noel Chan⁴

Affiliations

¹ Atherothrombosis and Vascular Biology Program, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
² Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia.
³ Department of Clinical Haematology, Alfred Hospital, Melbourne, Victoria, Australia.
⁴ Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada.

PMID: 33601429
DOI: 10.1055/s-0041-1723953

Abstract

Important advances in the understanding and management of venous thromboembolism (VTE) have enhanced our ability to diagnose, prevent, and treat VTE. In this narrative review, we discuss how recent advances in the understanding and management of VTE are changing practice, highlight ongoing unmet needs in VTE management, and outline how novel therapeutic targets with little or no influence on hemostasis may help address these unmet needs.

Publication types

Review

MeSH terms

Acute Disease
Anticoagulants / therapeutic use
Humans
Risk Factors
Venous Thromboembolism* / diagnosis
Venous Thromboembolism* / drug therapy
Venous Thrombosis

Substances

Anticoagulants